400828-91-3 Usage
Description
Tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate is a chemical compound characterized by the molecular formula C18H26N2O2. It is a derivative of piperidine, featuring an indoline and a tert-butyl ester functional group. tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate has garnered interest due to its potential pharmacological and biological activities, particularly as a G-protein-coupled receptor kinase 5 (GRK5) inhibitor. GRK5 is a protein kinase involved in the regulation of various receptor signaling pathways within the body. The unique structure and properties of tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate position it as a promising candidate for further research and development in medicinal chemistry and drug discovery.
Uses
Used in Pharmaceutical Research and Development:
Tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate is utilized as a GRK5 inhibitor for its potential role in modulating receptor signaling pathways. This makes it a valuable tool in the development of new therapeutic agents targeting various diseases and conditions where GRK5 activity is implicated.
Used in Medicinal Chemistry:
As a compound with a unique structure and functional groups, tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate serves as a starting point for the synthesis of novel compounds with potential medicinal properties. Its indoline and tert-butyl ester groups can be modified to explore new chemical entities with improved pharmacological profiles.
Used in Drug Discovery:
tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate's potential as a GRK5 inhibitor highlights its utility in drug discovery, where it can be further optimized to enhance its potency, selectivity, and pharmacokinetic properties. This may lead to the development of new drugs targeting GRK5-related diseases and conditions.
Used in Biological Research:
Tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate can be employed in biological research to study the role of GRK5 in cellular processes and disease mechanisms. This may provide insights into the development of targeted therapies and a better understanding of the underlying biology of various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 400828-91-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,0,8,2 and 8 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 400828-91:
(8*4)+(7*0)+(6*0)+(5*8)+(4*2)+(3*8)+(2*9)+(1*1)=123
123 % 10 = 3
So 400828-91-3 is a valid CAS Registry Number.
400828-91-3Relevant articles and documents
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models
Kamakolanu, Uma Gayathri,Meyer, Michael E.,Yasuda, Dennis,Polgar, Willma E.,Marti, Matteo,Mercatelli, Daniela,Pisanò, Clarissa Anna,Brugnoli, Alberto,Morari, Michele,Zaveri, Nurulain T.
, p. 2688 - 2704 (2020/03/31)
A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson'
PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS
-
Paragraph 0147-0149, (2018/06/15)
The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.
MULTIVALENT RAS BINDING COMPOUNDS
-
Paragraph 00905, (2017/07/23)
Described herein are compounds that modulate Ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered Ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in the treatment of cell proliferative disorders, including cancer.
